Analyst Price Targets — BLLN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 5, 2026 2:20 pm | Mark Massaro | BTIG | $140.00 | $72.66 | StreetInsider | BillionToOne Inc (BLLN) PT Lowered to $140 at BTIG |
| January 6, 2026 11:45 am | — | Guggenheim | $120.00 | $95.00 | TheFly | BillionToOne initiated with a Buy at Guggenheim |
| December 1, 2025 11:11 am | Mark Massaro | BTIG | $160.00 | $130.18 | TheFly | BillionToOne initiated with a Buy at BTIG |
| December 1, 2025 10:06 am | — | Wells Fargo | $110.00 | $130.18 | TheFly | BillionToOne initiated with an Equal Weight at Wells Fargo |
| December 1, 2025 9:41 am | — | Stifel Nicolaus | $145.00 | $130.18 | TheFly | BillionToOne initiated with a Buy at Stifel |
| December 1, 2025 7:45 am | David Westenberg | Piper Sandler | $150.00 | $130.18 | StreetInsider | Piper Sandler Starts BillionToOne Inc (BLLN) at Overweight |
| December 1, 2025 7:43 am | Tycho Peterson | Jefferies | $117.00 | $130.18 | StreetInsider | Jefferies Starts BillionToOne Inc (BLLN) at Hold |
Latest News for BLLN
Renowned physician executive and clinician-scientist joins BillionToOne to advance oncology medical strategy MENLO PARK, Calif., April 2, 2026 /PRNewswire/ -- BillionToOne , Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company focused on making highly accurate testing accessible to all, today announced the appointment of Allen Chen, MD, MBA, FASTRO, FACHE, as Vice President of Medical Affairs and…
Shares of Billiontoone, Inc. (NASDAQ: BLLN - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the ten analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have given a buy recommendation to the
BillionToOne, Inc. (BLLN) Q4 2025 Earnings Call Transcript
BillionToOne delivers strong growth in molecular diagnostics, achieving profitability and raising 2026 revenue guidance to $430–$445 million. BillionToOne's Q4 sales rose 113% to $96.1 million, driven by prenatal testing; oncology growth was slower sequentially but remains a long-term diversification lever. I view current guidance as conservative, with recent product launches and coverage deals not fully reflected…
Billiontoone, Inc. (NASDAQ: BLLN - Get Free Report) saw unusually-strong trading volume on Thursday following a stronger than expected earnings report. Approximately 713,533 shares changed hands during mid-day trading, an increase of 179% from the previous session's volume of 255,680 shares.The stock last traded at $72.51 and had previously closed at $80.83. The company reported $0.11
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for BLLN.
Senate Trading
No Senate trades found for BLLN.
U.S. House Trading
No House trades found for BLLN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.